Related Experiment Video

Updated: Nov 14, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.2K

Dabrafenib monotherapy in BRAF+ non-small cell lung cancer - our experience

Ondřej Fischer, Vítězslav Kolek, Denisa Rozsívalová

    Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
    |March 9, 2021
    PubMed
    Abstract

    Insights

    BRAF-mutated non-small cell lung cancer (NSCLC) patients can be treated with dabrafenib monotherapy. This offers an alternative when combination therapy is not possible, though access remains a challenge.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Genetics

    Background:

    • Activating BRAF mutations drive MAP kinase signaling and cell proliferation.
    • BRAF mutations are common in melanoma and occur in 1-2% of non-small cell lung cancer (NSCLC) cases.

    Observation:

    • Two case reports detail BRAF-positive NSCLC patients treated with third-line dabrafenib monotherapy.
    • A review of available data on dabrafenib monotherapy for BRAF-mutated NSCLC was conducted.

    Findings:

    • Dabrafenib monotherapy is a viable treatment option for BRAF-mutated NSCLC.
    • This approach is suitable for patients unable to receive combination therapy with trametinib.

    Implications:

    • BRAF inhibitors offer an alternative treatment for specific NSCLC patients.
    • Challenges in indication and reimbursement for NSCLC require individual treatment approvals.
    Keywords:
    dabrafenib – BRAF – lung cancer – non-small cell – NSCLC – monotherapy

    More Related Videos

    Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

    Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

    Published on: July 17, 2019

    6.3K
    Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

    Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

    Published on: March 1, 2024

    1.4K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.1K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.6K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.5K